These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34619433)

  • 1. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
    Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
    Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
    Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
    JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
    Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
    Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
    Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
    Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
    Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
    Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
    Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.
    Xu L; Liu J; Huang B; Kuang L; Gu J; Chen M; Zou W; Li J
    Cancer Med; 2021 Mar; 10(5):1656-1667. PubMed ID: 33527753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
    Fonseca R; Usmani SZ; Mehra M; Slavcev M; He J; Cote S; Lam A; Ukropec J; Maiese EM; Nair S; Potluri R; Voorhees PM
    BMC Cancer; 2020 Nov; 20(1):1087. PubMed ID: 33172403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A multicenter, prospective, phaseⅡ, single-arm study on the treatment of newly diagnosed multiple myeloma with domestic bortezomib in combination with lenalidomide and dexamethasone].
    Xie LN; Wang X; He Q; Wang H; Ma J; Zhang HY; Liu N; Jie GT; Xiao TW; Zhang H; Zhang HG; Li ZJ; Xing LJ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):571-576. PubMed ID: 39134489
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
    Arcani R; Venton G; Colle J; Suchon P; Ivanov V; Mercier C; Farnault L; Roche P; Lafage M; Brunet C; Azouza W; Pourroy B; Fanciullino R; Costello R
    Eur J Haematol; 2019 Oct; 103(4):385-392. PubMed ID: 31319001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis.
    Suzuki K; Tsukada N; Nishimura N; Nagata Y; Okazuka K; Mishima Y; Yokoyama M; Nishiwaki K; Ishida T; Yano S; Terui Y; Suzuki K
    Int J Hematol; 2020 Jan; 111(1):103-111. PubMed ID: 31673952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.